It found the industry loses $637 billion every year to medication non-adherence. Kottler, CEO and co-founder of HealthPrize, says he has been surprised by the industry’s apparent ignorance of ...

Objectives Patients with SLE take multiple medications. Within a large prospective longitudinal SLE cohort, we characterised ...

Improving health literacy is not just about providing information—it‘s about breaking down barriers, empowering communities, and ensuring that every ...

It might seem patently self-evident, but time critical medication needs to be taken on time. Yet, the reality is that, all too often, it isn't - and the consequences can be fatal.

(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name Journavx. It ...

Ultimately, prescription education may be key to curbing these issues.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

Nonadherence by SMA patients to their prescribed regimen of Evrysdi is linked to higher healthcare costs, a real-world U.S.